Physician profile
Mark L Silverman
NPI 1972620854
$1,007.45
in general payments reported to CMS, 2019-2025
16 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $12.36 · 2021: $221 · 2022: $151 · 2023: $60.03 · 2024: $49.19 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $282.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $368.34 | 2019-2022 | |
| Biogen, INC. | $167.28 | 2019-2025 | Tysabri, Vumerity |
| Janssen Pharmaceuticals, INC | $118.45 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $87.39 | 2021-2022 | |
| Adlon Therapeutics L.P. | $52.18 | 2021 | |
| Eisai INC. | $33.28 | 2023-2024 | |
| Biohaven Pharmaceuticals, INC. | $29.94 | 2021 | |
| Corium, LLC | $23.94 | 2023 | Adlarity |
| Alexion Pharmaceuticals, INC. | $23.87 | 2025 | Ultomiris |
| Livanova USA, INC. | $18.65 | 2025 | Vns Therapy |
| Astrazeneca Pharmaceuticals LP | $18.11 | 2024 | Andexxa |
| Cala Health, INC. | $17.85 | 2023 | Cala Trio |
| Pfizer INC. | $16.04 | 2024 | |
| Neurelis, INC. | $15.73 | 2022 | |
| Orexo US, INC. | $12.36 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $4.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.